PE20081477A1 - Formulacion liofilizada mab abeta - Google Patents

Formulacion liofilizada mab abeta

Info

Publication number
PE20081477A1
PE20081477A1 PE2007001764A PE2007001764A PE20081477A1 PE 20081477 A1 PE20081477 A1 PE 20081477A1 PE 2007001764 A PE2007001764 A PE 2007001764A PE 2007001764 A PE2007001764 A PE 2007001764A PE 20081477 A1 PE20081477 A1 PE 20081477A1
Authority
PE
Peru
Prior art keywords
antibody
abeta
mab
lyophilized formulation
histidine
Prior art date
Application number
PE2007001764A
Other languages
English (en)
Spanish (es)
Inventor
Pierre Goldbach
Hanns-Christian Mahler
Robert Mueller
Christine Wurth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39190366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081477(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081477A1 publication Critical patent/PE20081477A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2007001764A 2006-12-11 2007-12-11 Formulacion liofilizada mab abeta PE20081477A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06025590 2006-12-11

Publications (1)

Publication Number Publication Date
PE20081477A1 true PE20081477A1 (es) 2008-10-18

Family

ID=39190366

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001764A PE20081477A1 (es) 2006-12-11 2007-12-11 Formulacion liofilizada mab abeta

Country Status (21)

Country Link
US (1) US20110070225A1 (https=)
EP (1) EP2094729A1 (https=)
JP (1) JP2010512356A (https=)
KR (1) KR20090104017A (https=)
CN (1) CN101553504A (https=)
AR (1) AR064220A1 (https=)
AU (1) AU2007331712A1 (https=)
BR (1) BRPI0721097A2 (https=)
CA (1) CA2671968A1 (https=)
CL (1) CL2007003583A1 (https=)
CR (1) CR10823A (https=)
EC (1) ECSP099403A (https=)
IL (1) IL198963A0 (https=)
MA (1) MA30975B1 (https=)
MX (1) MX2009006199A (https=)
NO (1) NO20092586L (https=)
PE (1) PE20081477A1 (https=)
RU (1) RU2009126420A (https=)
TW (1) TW200831133A (https=)
WO (1) WO2008071394A1 (https=)
ZA (1) ZA200904014B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
CA2611726C (en) 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
MY155286A (en) * 2005-12-12 2015-09-30 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylated in the variable region
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
WO2009155513A2 (en) * 2008-06-20 2009-12-23 Novartis Ag Immunoglobulins with reduced aggregation
ES2531385T3 (es) * 2008-09-19 2015-03-13 Hoffmann La Roche Formulación que comprende un anticuerpo contra la selectina P
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
MX2011005051A (es) * 2008-11-17 2011-06-01 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010100179A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
EP2501408B1 (en) * 2009-11-20 2020-05-27 Biocon Limited Formulations of antibody
BR112012013148A2 (pt) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
NZ601117A (en) 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012028683A1 (en) * 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
RS54644B1 (sr) * 2012-03-08 2016-08-31 F. Hoffmann-La Roche Ag Formulacija abeta antitela
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
TW201513882A (zh) * 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
CN107108715A (zh) 2014-10-24 2017-08-29 默沙东公司 胰高血糖素和glp‑1受体的共激动剂
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN104946616A (zh) * 2015-05-12 2015-09-30 骏实生物科技(上海)有限公司 一种用于体外诊断试剂的通用固体稳定剂及其使用方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
RS64263B1 (sr) * 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
MX2018003298A (es) * 2015-09-22 2018-06-20 Pfizer Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
CN106620691B (zh) * 2015-11-04 2020-08-21 信达生物制药(苏州)有限公司 一种重组全人源抗ctla-4单克隆抗体制剂及其应用
CN115400220A (zh) 2015-12-30 2022-11-29 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
CN118370815A (zh) * 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
CN108373494A (zh) * 2018-02-27 2018-08-07 武汉伊艾博科技有限公司 一种防止重组蛋白质降解的保护技术
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂
CN112741804A (zh) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
EP4159236A4 (en) 2020-05-29 2024-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
US20230365667A1 (en) * 2020-09-30 2023-11-16 Merck Sharp & Dohme Llc Binding proteins and antigen binding fragments thereof that bind abeta
AU2024283314A1 (en) 2023-05-31 2025-11-13 F. Hoffmann-La Roche Ag Therapeutic use of bispecific anti-abeta/tfr antibodies
CN117088974B (zh) * 2023-08-14 2024-02-13 武汉健昊生物科技有限公司 一种抗体保存液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
MY155286A (en) * 2005-12-12 2015-09-30 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylated in the variable region
JP2009531371A (ja) * 2006-03-28 2009-09-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤

Also Published As

Publication number Publication date
WO2008071394A1 (en) 2008-06-19
NO20092586L (no) 2009-07-17
MA30975B1 (fr) 2009-12-01
EP2094729A1 (en) 2009-09-02
CA2671968A1 (en) 2008-06-19
CN101553504A (zh) 2009-10-07
ZA200904014B (en) 2010-04-28
RU2009126420A (ru) 2011-01-20
CR10823A (es) 2009-08-12
MX2009006199A (es) 2009-06-22
IL198963A0 (en) 2011-08-01
TW200831133A (en) 2008-08-01
AR064220A1 (es) 2009-03-18
AU2007331712A2 (en) 2009-07-30
AU2007331712A1 (en) 2008-06-19
JP2010512356A (ja) 2010-04-22
ECSP099403A (es) 2009-07-31
BRPI0721097A2 (pt) 2014-07-01
CL2007003583A1 (es) 2008-07-18
KR20090104017A (ko) 2009-10-05
US20110070225A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
PE20081477A1 (es) Formulacion liofilizada mab abeta
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
PE20091327A1 (es) Composicion farmaceutica que comprende anticuerpos monoclonales
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20110302A1 (es) Formulacion farmaceutica de un anticuerpo contra p-selectina
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
PE20142407A1 (es) Formulacion de anticuerpos
CL2010000426A1 (es) Anticuerpo humano que se une al ligando para el ox40 (ox40l o gp34) humano; metodo de produccion; y composicion farmaceutica que lo comprende (div. sol. n°2389-05).
AR079746A1 (es) Formulacion farmaceutica de anticuerpo
PE20120359A1 (es) Formulacion con anticuerpo
PE20070116A1 (es) Formulacion de anticuerpos estables
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
UA99815C2 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CL2007003761A1 (es) Composicion liquida de limpieza personal que comprende isetionatos de acilo graso, cosurfactante, alcanolamida y/o alquilaminaoxido, acidos grasos de cadena recta o mezcla con alcoholes grasos de cadena recta y/o aceites de hidrocarburo alifatico, la
EA201200475A1 (ru) Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20
PY0401585A (es) Formulaciones farmaceuticas liquidas de palonosetron
PE20140166A1 (es) Composicion farmaceutica que comprende deferasirox
CL2007001185A1 (es) Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
PE20081610A1 (es) Formulaciones de anticuerpos anti-il-13 y usos de los mismos
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
NZ630885A (en) Antibody formulation
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
AR067011A1 (es) Formulaciones de anticuerpos
CL2013003214A1 (es) Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol.

Legal Events

Date Code Title Description
FD Application declared void or lapsed